Scottish Medicines Consortium blocks access to Actelion’s PAH drug on NHS Scotland

Actelion says it is disappointed by the decision made by Scottish cost regulators to refuse NHS funding for pulmonary arterial hypertension drug Uptravi. The Scottish Medicines Consortium (SMC) issued guidance not recommending use of Uptravi (selexipag) for a sub-population of adult patients with the potentially life-threatening condition, which leads to an increase in blood pressure

Continue Reading